Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

1DANUBE (D vs C - PDL1>25%), 20201DANUBE (DT vs C - PDL1>25%), 2020durvalumab alone vs. durvalumab plus tremelimumab 1.20 [0.87; 1.65]1.20 [0.87;1.65]durvalumab alone vs. durvalumab plus tremelimumab 1.20 [0.87; 1.65]durvalumab alone vs. gemcitabine plus platin 0.89 [0.71; 1.11]0.89 [0.71;1.11]durvalumab alone vs. gemcitabine plus platin 0.89 [0.71; 1.11]durvalumab plus tremelimumab vs. durvalumab alone 0.83 [0.60; 1.14]0.83 [0.60;1.14]durvalumab plus tremelimumab vs. durvalumab alone 0.83 [0.60; 1.14]durvalumab plus tremelimumab vs. gemcitabine plus platin durvalumab plus tremelimumab better 0.74 [0.59; 0.93]0.74 [0.59;0.93]durvalumab plus tremelimumab vs. gemcitabine plus platin durvalumab plus tremelimumab better 0.74 [0.59; 0.93]gemcitabine plus platin vs. durvalumab alone 1.12 [0.90; 1.40]1.12 [0.90;1.40]gemcitabine plus platin vs. durvalumab alone 1.12 [0.90; 1.40]gemcitabine plus platin vs. durvalumab plus tremelimumab durvalumab plus tremelimumab better 1.35 [1.08; 1.70]1.35 [1.08;1.70]gemcitabine plus platin vs. durvalumab plus tremelimumab durvalumab plus tremelimumab better 1.35 [1.08; 1.70]gemcitabine plus platindurvalumab alonedurvalumab plus tremelimumabdirect evidencenetwork meta-analysis
T vs. C gemcitabine plus platindurvalumab alonedurvalumab plus tremelimumab
gemcitabine plus platin---1.12
0.90; 1.40		1.35
1.08; 1.70
durvalumab alone0.89
0.71; 1.11		---1.20
0.87; 1.65
durvalumab plus tremelimumab0.74
0.59; 0.93		0.83
0.60; 1.14		---

pathologies: 157 - treatments: 634,861 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons